GH Research PLC (GHRS) Form 6-K — May 21, 2026
GH Research PLC (GHRS) announced it will present three posters at the American Society of Clinical Psychopharmacology Annual Meeting in Miami, highlighting robust Phase 2b clinical data for its investigational psychedelic drug GH001 (mebufotenin) in treatment-resistant depression. The data demonstrates rapid and sustained efficacy, with GH001 reducing MADRS anhedonia scores by 9.9 points versus placebo at Day 8 (P<0.0001) and maintaining significant improvements in depression, anxiety, and quality of life through a 6-month open-label extension.
Key figures
- Ole completers
- 63
- Cohen d anhedonia
- -2.00
- Patient count gh001
- 40
- Remission rate day8
- 54-64%
- Cgi s reduction day8
- -2.5 points vs placebo
- Ham a reduction day8
- -10.0 points vs placebo
- Patient count placebo
- 41
- Remission rate month6
- 62-86%
- Madrs total reduction day8
- -15.5 points vs placebo
- Q les q sf improvement day8
- 21.4 points vs placebo
- Madrs anhedonia reduction day8
- -9.9 points vs placebo
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.